Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind randomized trial of isavuconazole versus voriconazole for primary treatment of invasive mould disease
2006-003868-59Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of isavuconazole in invasive aspergillosis (IA) and invasive mycoses (2 arms), sponsored by Astellas Pharma. Primary endpoint: All-cause mortality through Day 42. Started Nov 2006; status: completed.
02
Drugs
isavuconazole
03
Conditions
invasive aspergillosis (IA)invasive mycoses
Beyond the preview
Go deeper on 2006-003868-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003868-59.